



06-21-04

IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Di Pietro et al.

Serial No.: 10/804,915

Group Art Unit No.: 1626

Filed: March 19, 2004

Examiner: Not yet assigned

For: HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Docket No.: A-846

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Joseph W. Bullock  
Attorney/Agent for Applicant(s)  
Registration No.: 37,103  
Phone: (805) 447-7966  
Date: June 18, 2004

**EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number: EV351338382US Date of Deposit: June 18, 2004


I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

SL. ST. ANDREW  
Printed Name

SL. St. Andrew  
Signature

Please send all future correspondence to:

US Patent Operations/JWB  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799



Modified Form PTO-1449

Atty. Docket No.

A-846

Serial No.

10/804,915

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Di Pietro et al.

Filing Date

March 19, 2004

Group

1626

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	JP 57149341 A2	14 Sep 1982	Japan				X
	B2	WO 03/082272 A1	9 Oct 2003	PCT				

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

	C1	Breier et al., "The role of vascular endothelial growth factor in blood vessel formation", Trends in Cell Biology, 6:454-456 (1996).
	C2	Connell et al., "Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000 – September 2000", Expert Opinion on Therapeutic Patents, 1:77-114 (2001).
	C3	Chemical Abstracts 98:90489, English abstract for patent B1 referenced above.

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.